Skip to main content

Advertisement

SpringerLink
Log in

The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma

  • Original Scientific Report
  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Docetaxel, cisplatin and fluorouracil (DCF) is a candidate neoadjuvant chemotherapy (NAC) regimen for esophageal squamous cell carcinoma (ESCC). Although the efficacy and safety of DCF have been reported, the markers that predict the patient’s response are still unknown. The aim of this study was to identify the predictive markers for a response to NAC with DCF in patients with ESCC.

Methods

A total of 79 patients who received preoperative DCF followed by esophagectomy between August 2008 and December 2014 were enrolled in this study. All of the patients completed 2 preoperative courses of DCF. The clinical and pathological responses to DCF were investigated, and the associations between the pathological response, the clinicopathological factors and the prognosis were retrospectively analyzed.

Results

Among the 79 patients, the pathological response to DCF (evaluated according to the Japanese Classification of Esophageal Cancer) was grade 3 (complete pathological response) in 7 patients (8.9 %), grade 2 in 13 patients (16.5 %), grade 1b in 8 patients (10.1 %) and grade 1a in 51 patients (64.6 %). A good pathological response (grade 2–3) was significantly associated with both favorable disease-free survival (P = 0.0051) and favorable cancer-specific survival (P = 0.0366). A multivariate analysis revealed that a good clinical response (HR 13.743, 95 % CI 2.455–76.917) and the presence of serum p53 antibody before treatment (HR 3.987, 95 % CI 1.103–14.416) were independent predictors of good pathological response.

Conclusions

The presence of serum p53 antibody can be used as a novel, noninvasive predictor of the pathological tumor response to NAC with DCF in ESCC patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90

    Article  PubMed  Google Scholar 

  2. Allum WH, Stenning SP, Bancewicz J et al (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(5062–506):7

    Google Scholar 

  3. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial Lancet (London, England) (2002): 359; 1727–1733

  4. van Hagen P, Hulshof MC, van Lanschot JJ et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. New Engl J Med 366(2074–208):4

    Google Scholar 

  5. Ando N, Iizuka T, Ide H et al (2003) Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study–JCOG9204. J Clin Oncol Off J Am Soc Clin Oncol 21:4592–4596

    Article  Google Scholar 

  6. Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68–74

    Article  PubMed  Google Scholar 

  7. Watanabe M, Nagai Y, Kinoshita K et al (2011) Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion 83:146–152

    Article  CAS  PubMed  Google Scholar 

  8. Nomura M, Oze I, Abe T et al (2015) Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis. Cancer Chemother Pharmacol 76:357–363

    Article  CAS  PubMed  Google Scholar 

  9. Watanabe M, Baba Y, Yoshida N et al (2014) Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. Ann Surg Oncol 21:2838–2844

    Article  PubMed  Google Scholar 

  10. Yoshida N, Watanabe M, Baba Y, et al. (2014) Influence of preoperative docetaxel, cisplatin, and 5-fluorouracil on the incidence of complications after esophagectomy for resectable advanced esophageal cancer Diseases of the esophagus. Off J Int Soc Dis Esophagus/I.S.D.E 27:374–379

  11. Law S, Fok M, Chow S et al (1997) Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 114(210–21):7

    Google Scholar 

  12. Ancona E, Ruol A, Santi S et al (2001) Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91:2165–2174

    Article  CAS  PubMed  Google Scholar 

  13. Yano M, Takachi K, Doki Y, et al. (2006) Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus Diseases of the esophagus. Off J Int Soc Dis Esophagus/I.S.D.E 19:158–163

  14. Bollschweiler E, Holscher AH, Schmidt M, et al. (2015) Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment Chin J Cancer Res Chung-kuo Yen Cheng Yen Chiu 27:221–230

  15. Tanaka T, Fujita H, Sueyoshi S et al (2007) Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy 53(449–45):3

    Google Scholar 

  16. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States. Nat Cancer Inst Can J Nat Cancer Inst 92:205–216

    Article  CAS  Google Scholar 

  17. Takahashi H, Arimura Y, Yamashita K et al (2010) Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 5:122–128

    Google Scholar 

  18. Yamasaki M, Miyata H, Tanaka K et al (2011) Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology 80:307–313

    Article  CAS  PubMed  Google Scholar 

  19. Osaka Y, Shinohara M, Hoshino S et al (2011) Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. Anticancer Res 31:633–638

    CAS  PubMed  Google Scholar 

  20. Tamura S, Imano M, Takiuchi H et al (2012) Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 32:1403–1408

    CAS  PubMed  Google Scholar 

  21. Hara H, Tahara M, Daiko H et al (2013) Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104:1455–1460

    Article  CAS  PubMed  Google Scholar 

  22. Soussi T, Legros Y, Lubin R et al (1994) Multifactorial analysis of p53 alteration in human cancer: a review International journal of cancer. J Int du Cancer 57:1–9

    Article  CAS  Google Scholar 

  23. Hollstein MC, Metcalf RA, Welsh JA et al (1990) Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 87:9958–9961

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Coggi G, Bosari S, Roncalli M et al (1997) p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 79:425–432

    Article  CAS  PubMed  Google Scholar 

  25. Sarbia M, Porschen R, Borchard F et al (1994) p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 74:2218–2223

    Article  CAS  PubMed  Google Scholar 

  26. Murata A, Baba Y, Watanabe M, et al. (2013) p53 immunohistochemical expression and patient prognosis in esophageal squamous cell carcinoma Medical oncology (Northwood, London, England) 30:728

  27. von Brevern MC, Hollstein MC, Cawley HM et al (1996) Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. Cancer Res 56:4917–4921

    Google Scholar 

  28. Collet B, Raoul J, Leberre N et al (1997) Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus. Int J Oncol 11:617–621

    CAS  PubMed  Google Scholar 

  29. Sobti RC, Parashar K (1998) A study on p53 protein and anti-p53 antibodies in the sera of patients with oesophageal cancer. Mutat Res 422:271–277

    Article  CAS  PubMed  Google Scholar 

  30. Ralhan R, Arora S, Chattopadhyay TK et al (2000) Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India International journal of cancer. J Int du Cancer 85:791–795

    Article  CAS  Google Scholar 

  31. Shimada H, Nabeya Y, Okazumi S et al (2002) Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 132:41–47

    Article  PubMed  Google Scholar 

  32. Takahashi K, Miyashita M, Nomura T et al (2007) Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma Diseases of the esophagus. Off J Int Soc Dis Esophagus/I.S.D.E 20:117–122

    Article  CAS  Google Scholar 

  33. Shimada H, Takeda A, Arima M et al (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683

    Article  CAS  PubMed  Google Scholar 

  34. Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629

    Article  CAS  PubMed  Google Scholar 

  35. Yamasaki M, Miyata H, Fujiwara Y et al (2010) p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Annal Surg Oncol 17:634–642

    Article  Google Scholar 

  36. Makino T, Yamasaki M, Miyata H et al (2010) p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Annal Surg Oncol 17:804–811

    Article  Google Scholar 

  37. Kandioler D, Schoppmann SF, Zwrtek R et al (2014) The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. J Thorac Cardiovasc Surg 148:2280–2286

    Article  CAS  PubMed  Google Scholar 

  38. Shimada H, Okazumi S, Takeda A et al (2001) Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg Today 31:591–596

    Article  CAS  PubMed  Google Scholar 

  39. Gluck S, Ross JS, Royce M et al (2012) TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat 132:781–791

    Article  PubMed  Google Scholar 

  40. Kandioler-Eckersberger D, Ludwig C, Rudas M et al (2000) TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients Clinical cancer research: an official journal of the American Association for. Cancer Res 6:50–56

    CAS  Google Scholar 

  41. Di Leo A, Tanner M, Desmedt C et al (2007) p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Annal Oncol Off J Eur Soc Med Oncol/ESMO 18:997–1003

    Article  Google Scholar 

  42. Hawkins DS, Demers GW (1996) Galloway DA Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892–898

    CAS  PubMed  Google Scholar 

  43. Wahl AF, Donaldson KL, Fairchild C et al (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2:72–79

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan

    Yukiharu Hiyoshi, Naoya Yoshida, Junji Kurashige, Yoshifumi Baba, Yasuo Sakamoto & Hideo Baba

  2. Esophageal Surgery, Gastroenterological Surgery, Gastroenterology Center, The Cancer Institute Hospital of JFCR (Japanese Foundation for Cancer Research), Koto, Japan

    Masayuki Watanabe

Authors
  1. Yukiharu Hiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoya Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masayuki Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junji Kurashige
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshifumi Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yasuo Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideo Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideo Baba.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hiyoshi, Y., Yoshida, N., Watanabe, M. et al. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. World J Surg 41, 480–486 (2017). https://doi.org/10.1007/s00268-016-3649-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-016-3649-0

Keywords

Search

Navigation